Genprex reports positive preclinical data for diabetes gene therapy GPX-002 at ADA

Genprex, Inc.

Alpha cells in Type 1 diabetes mouse models transdifferentiated to insulin-secreting beta-like cells after GPX-002 infusion.
In diabetic non-human primates, GPX-002 improved glucose tolerance and reduced insulin requirements at one month post-infusion.
Three-month immunosuppression with rituximab, rapamycin, and steroids largely prevented anti-viral immunity in NHPs.
Continued studies will evaluate GPX-002 efficacy after six months of immunosuppression in NHP models.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.